ISRG INTUITIVE SURGICAL INC
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1035267 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.5%
TTM net income YoY7.7%
TTM EPS YoY9.4%
Revenue 3-yr CAGR19.1%
Net income 3-yr CAGR24.9%
Margins
Gross margin67.2%
Operating margin28.4%
Net margin25.5%
FCF margin31.1%
EBITDA margin—
Returns
ROE18.0%
ROA15.3%
ROIC (approx.)19.9%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets16.7%
Debt / equity0.00x
Current ratio3.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.38x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.06B | $8.35B |
| Cost of revenue | $3.42B | $2.72B |
| Gross profit | $6.64B | $5.63B |
| R&D expense | $1.31B | $1.15B |
| SG&A expense | $2.38B | $2.14B |
| Operating income | $2.95B | $2.35B |
| Pretax income | $3.31B | $2.67B |
| Income tax | $434.80M | $336.30M |
| Net income | $2.86B | $2.32B |
| EBITDA | $3.55B | $2.79B |
| EPS (basic) | 8.00 | 6.54 |
| EPS (diluted) | 7.87 | 6.42 |
| Weighted avg. shares (diluted) | 362.70M | 362.00M |
| Balance sheet | ||
| Cash & equivalents | $3.37B | $2.06B |
| Short-term investments | $2.57B | $1.99B |
| Receivables | $1.53B | $1.23B |
| Inventory | $1.84B | $1.49B |
| Current assets | $9.78B | $7.11B |
| PP&E, net | $5.34B | $4.65B |
| Goodwill | $370.30M | $347.50M |
| Intangibles | $17.10M | $23.00M |
| Total assets | $20.46B | $18.74B |
| Current liabilities | $2.01B | $1.75B |
| Total liabilities | $2.52B | $2.21B |
| Shareholders' equity | $17.82B | $16.43B |
| Shares outstanding | 355.10M | 356.60M |
| Cash flow statement | ||
| Operating cash flow | $3.03B | $2.42B |
| Capital expenditure | $539.80M | $1.11B |
| Free cash flow | $2.49B | $1.30B |
| Investing cash flow | $665.80M | -$3.27B |
| Financing cash flow | -$2.36B | $150.90M |
| Depreciation & amortization | $600.00M | $439.00M |
| Stock-based compensation | $788.20M | $676.80M |
| Share buybacks | $2.30B | $0 |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.